iOnctura appoints Paul Sekhri as Chair of its Board of Directors
iOnctura, a private clinical-stage oncology company, appointed Paul Sekhri as Chair of its Board effective immediately, replacing Dr. Mark Velleca. Sekhri is a life sciences veteran who currently serves as Independent Chair of Apnimed (APMD), CEO of vTv Therapeutics (VTVT), and a director of Veeva Systems (VEEV).
Key figures
- Sekhri board roles
- more than 40 boards, 18 as Chair
- Longboard acquisition value
- $2.6 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.